Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 康为世纪是一家立足于生命科学领域的创新型企业，立足分子检测底层核心技术的自主研发，在酶原料、核酸保存、样本前处理领域有十余年的研发积累，目前，康为世纪累积投资数亿元，总面积超8万余平米，拥有职工600多人，产品达700余种，构建了酶原料、核酸保存、核酸提取纯化、荧光定量PCR、基因测序和核酸质谱6个技术平台，实现了分子检测“核心原料+试剂盒+检测服务”的一体化布局。 康为世纪专长于基因检测试剂的创新，从样本采集与保存，到核酸提取，到分子检测，均实现了自主创新。在医学检测领域，康为世纪旗下拥有多家医学检验所，建立了包括荧光定量PCR、二代测序和核酸质谱在内的多种分子检测技术平台，开发有各类分子检测服务项目一百余项。 未来，康为世纪将秉承推动祖国生命科学事业发展的信念和使命感，秉随“诚信、挚爱、专注、创新”的精神，贯彻“健康有为，合作共赢”的经营理念，持续为全球生命科学研究与应用机构提供创新型的生物产品与服务，为民生健康提供科技保障，让每一个生命健康有为！
Main Business 分子检测底层核心技术的自主研发。
Legal Representative 王春香
Top Executives
董事长：王春香
董事：沈浩,殷剑峰,戚玉柏,庄志华
独立董事：肖潇,胡宗亥,李映红
Top 5 Shareholder
Shareholder name Nature Holding Date
北京康为世纪生物科技有限公司限售股44.80%30/09/2024
泰州康为共创企业管理咨询合伙企业（有限合伙）限售股19.20%30/09/2024
中国工商银行股份有限公司－融通健康产业灵活配置混合型证券投资基金流通A股2.53%30/09/2024
江苏康为世纪生物科技股份有限公司回购专用证券账户流通A股2.12%30/09/2024
中信证券－中信银行－中信证券康为世纪员工参与科创板战略配售集合资产管理计划流通A股1.52%30/09/2024
Company Secretary 戚玉柏
Solicitors 上海市通力律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 0523-86200880
Fax No 0523-86200880
Website www.cwbio.com
Email cw688426@cwbio.cn;IRM@cwbio.cn
Company Address
Register: 泰州市医药高新区泽兰路18号
Office: 江苏省泰州市医药高新区泽兰路18号
Listing Date 25/10/2022
Shares Capital
Shares Capital: 112,493,716
Total A Share: 112,493,716
Listed A Share: 37,993,332
Non-tradable A Share: 74,500,384
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.752
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 14.824
Market Capitalization(RMB) 0.955B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.